business / news / / Devdiscourse
Neurocrine Biosciences is making a significant move into the realm of metabolic disorders with a $2.9 billion acquisition of Soleno Therapeutics.
Neurocrine Biosciences is acquiring Soleno Therapeutics for $2.9 billion.
KEY POINTS
- The acquisition gives Neurocrine access to Vykat XR, approved for Prader-Willi syndrome in the U.S.
- Neurocrine is expanding its rare-disease treatment portfolio through this acquisition.
- Eli Lilly's Foundayo and Novo Nordisk's Wegovy pills are driving increased consumer demand for weight-loss medications.
COMPANIES
Summarized by Newsio from Devdiscourse. How we summarize →